NCT04620200已完成2 期
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Patients Prior to Standard of Care Surgery; the MATISSE Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Histopathological response rate at standard of care
研究概览
简要总结
To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous squamous cell carcinoma.
详细描述
This is an investigator-initiated randomized non-comparative phase II trial consisting of 40 patients with resectable stage III-IVa CSCC randomized 1:1 to ARM A: 2 courses of nivolumab 3 mg/kg in week 0 and 2, or ARM B: 2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0. Both treatment arms are neo-adjuvant and applied prior to standard of care (consisting of surgery at week 4 with or without adjuvant radiotherapy).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older.
- •Patient is able to understand and comply with the protocol requirements and has signed the informed consent form.
- •World Health Organization (WHO) Performance Status 0 or 1 (Appendix B).
- •Patients with histologically or cytologically confirmed, primary or recurrent stage III-IVA CSCC of all body sites.
- •Patients with histologically or cytologically proven stage I-II CSCC, only in the case of:
- •Presence of multifocal disease for which extensive and/or mutilating surgery is necessary (e.g. near-total scalp resection).
- •Situated in an anatomical localization that necessitates extensive and/or mutilating surgery (e.g. orbital exenteration).
- •Eligible for standard-of-care, curatively intended surgery with or without adjuvant radiotherapy.
- •Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109 /L, Neutrophils ≥1.5x109 /L, Platelets ≥100 x109 /L, Hemoglobin ≥5.5 mmol/L, Creatinine ≤1.5x ULN, AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤1.5 X ULN (except subjects with Gilbert Syndrome, who are eligible when total bilirubin < 3.0 mg/dL).
- •Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. They should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of the investigational drug.
- •WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) prior to the start of nivolumab or nivolumab + ipilimumab.
- •Men who are sexually active with WOCBP must use a contraceptive method with a failure rate of less than 1% per year and will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product. Surgically sterile or azoospermic men do not require aforementioned contraception.
排除标准
- •Distantly metastasized (stadium IVb) CSCC.
- •SCC localized in a mucosal surface (i.e. anus, vulva, penis or mucosal portion of lip).
- •Patients for whom SOC consists of definitive (brachy)radiotherapy.
- •Primary or recurrent CSCC appearing in an area that has been previously irradiated.
- •Prior anti-CTLA4 or anti-PD1 immunotherapy.
- •Active human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •A positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C antibody (HCV Ab).
- •Subjects with any active autoimmune disease or a documented history of autoimmune disease, except for:
- •Subjects with vitiligo
- •Resolved childhood asthma/atopy
- •Residual hypothyroidism due to an autoimmune condition requiring only hormone replacement
- •Psoriasis not requiring systemic treatment
- •Any condition not expected to recur in the absence of an external trigger.
- •Underlying medical conditions that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or AE.
- •A concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
- •Pregnant or nursing.
- •A history of allergy to study drug components and/or a history of severe hypersensitivity to any monoclonal antibody.
- •Use of other investigational drugs 30 days before study drug administration and 5 half times before study inclusion.
- •Use of prohibited medication at start of study period
研究组 & 干预措施
ARM A
Experimental
2 courses of nivolumab 3 mg/kg in week 0 and 2 prior to standard of care
干预措施: Nivolumab (Drug)
ARM B
Experimental
2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0 prior to standard of care
干预措施: Nivolumab (Drug)
ARM B
Experimental
2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0 prior to standard of care
干预措施: Ipilimumab (Drug)
结局指标
主要结局
Histopathological response rate at standard of care
时间窗: At time of standard of care at week 4
The proportion of viable tumor cells left in the resected specimen, to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of SOC (surgery ± RT).
次要结局
- Recurrence free survival (RFS) at 2 years FU of responders versus non-responders to neo-adjuvant ICI(At 2-years follow up)
- Sensitivity and specificity of tumor biopsies, clinical photography, FDG-PET and (functional)MRI compared to the histopathological tumor response to neo-adjuvant immunotherapy(At time of standard of care at week 4)
- Numbers of participants without significant delay (>1 week) or cancelation of SOC surgery due to immune-related toxicity(At time of standard of care at week 4)
- Overall survival (OS) at 2 years FU of responders versus non-responders to neo-adjuvant ICI(At 2-years follow up)
- The number of patients with AE (rate and type) acoording to NCI CTCAE v.5.0 up to 2 years FU after SOC(At 2-years follow up)
- Clinical response of potentially additional AK surface areas after ICI identified by digital clinical photography on day 0, day 14, day 28 and every 6 months during FU up to 2 years.(On day 0, day 14, day 28 (at time of surgery) and every 6 months during FU up to 2 years.)
- Quality of life as measured by H&N 35(At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU)
- Quality of life as measured by the EQ5D,(At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU)
- Quality of life as measured by EORTC QLQ-C30(At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU)
- Quality of life as measured by the cancer worry scale (CWS)(At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU)
- Quality of life as measured by the IT questionnaire(At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU)
- Quality of life as measured by the sexuality questionnaire(At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816on-Small Cell Lung CancerJPRN-jRCT2080223597Bristol-Myers Squibb K.K.642
已完成
1 期
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorNerve Sheath TumorsNCT04465643Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins13
已完成
2 期
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma (HCC)NCT03510871National Health Research Institutes, Taiwan43
进行中（未招募）
2 期
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerLocally Advanced Rectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8NCT04751370National Cancer Institute (NCI)31
终止
2 期
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCNon-small Cell Lung CancerNCT03425331Dana-Farber Cancer Institute5